These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7512895)

  • 1. [Prostate carcinoma].
    Huland H
    Dtsch Med Wochenschr; 1994 Apr; 119(16):605. PubMed ID: 7512895
    [No Abstract]   [Full Text] [Related]  

  • 2. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment: expected duration stage by stage.
    Schröder FH
    Prostate Suppl; 2000; 10():26-31. PubMed ID: 11056490
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.
    Hayashi N; Urashima M; Ikemoto I; Kuruma H; Arai Y; Kuwao S; Baba S; Egawa S
    Prostate Cancer Prostatic Dis; 2007; 10(1):60-5. PubMed ID: 17003775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
    D'Amico AV; Desjardin A; Chung A; Chen MH; Schultz D; Whittington R; Malkowicz SB; Wein A; Tomaszewski JE; Renshaw AA; Loughlin K; Richie JP
    Cancer; 1998 May; 82(10):1887-96. PubMed ID: 9587121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of stage A1 prostate cancer: the case for treatment.
    Bahnson RR
    Semin Urol; 1993 May; 11(2):54-7. PubMed ID: 7689739
    [No Abstract]   [Full Text] [Related]  

  • 7. [Surgical therapy of locally confined prostate carcinoma].
    Bendhack ML; Miller S; Ackermann R
    Praxis (Bern 1994); 1997 Nov; 86(46):1819-24. PubMed ID: 9454283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive retraction artefact predicts biochemical recurrence-free survival in prostatic carcinoma.
    Tomas D; Spajić B; Milošević M; Demirović A; Marušić Z; Krušlin B
    Histopathology; 2011 Feb; 58(3):447-54. PubMed ID: 21323967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with positive surgical margins following radical prostatectomy.
    Richie JP
    Urol Clin North Am; 1994 Nov; 21(4):717-23. PubMed ID: 7526517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the pathology results of radical prostatectomy from preoperative information: a validation study.
    Vollmer RT; Keetch DW; Humphrey PA
    Cancer; 1998 Oct; 83(8):1567-80. PubMed ID: 9781951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml.
    Stephan C; Jung K; Cammann H
    Cancer; 2004 May; 100(9):1989-90; author reply 1989-90. PubMed ID: 15112283
    [No Abstract]   [Full Text] [Related]  

  • 16. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R; Roobol M; Schröder FH; van der Kwast TH
    Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PSA: one test with three uses.
    Harv Mens Health Watch; 2001 Jul; 5(12):1-4. PubMed ID: 11511459
    [No Abstract]   [Full Text] [Related]  

  • 18. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early versus delayed intervention for prostate cancer: the case for early intervention.
    Loeb S; Catalona WJ
    Nat Clin Pract Urol; 2007 Jul; 4(7):348-9. PubMed ID: 17563779
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.